

### ANRS | MIE Scientific Days in Vietnam

Towards ending epidemics

15<sup>th</sup> to 16<sup>th</sup> of November, 2023

# Mpox vaccination: knowledge gap

Dr. Lương Nguyễn Liêm Bình (MD, PhD)

Hôpital Cochin Port Royal, Paris





# **Outline**



What we knew

What happened

What we learned

What we still do not know

# Outline



What we knew

What happened


What we learned

What we still do not know

# Monkey pox (Mpox)



- Poxviridae, identified in 1970
- Zoonosis
- Little data (Petersen, 2019, IDNA):
  - Incubation : 5 to 21 days
  - Mortality: 1 to 10% (children)
- Few imported cases
  - 71 cases in the US (2003)
  - 7 cases in UK (2019-2021)



# **Mpox vaccination**



- Small Pox vaccine to prevent Monkey pox (mpox)
  - 3 generations : Dryvax → ACAM 2000 → Jynneos ®/ Imvanex®



### **Pre-exposure**

- Zaire (DRC), 1981-1986
- ACAM-2000 (2<sup>nd</sup> gen)
- 3% probability of being infected

Human monkeypox: secondary attack rates

Z. JEŽEK, B. GRAB, M. V. SZCZENIOWSKI, K. M.PALUKU, & M. MUTOMBO

Bulletin of the World Health Organization, 66 (4): 465-470 (1988)

#### **Post-exposure**

- Historical study on smallpox, use of delphi (Massousi, 2003, JID)
- Animal challenge

# Outline




What we knew

What happened


What we learned

What we still do not know

























Affect mostly MSM







### nature medicine

Explore content 
About the journal 
Publish with us 
Subscribe


nature > nature medicine > correspondence > article

CORRESPONDENCE | 13 July 2022

# A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox

Liem Binh Luong Nguyen <sup>™</sup>, Jade Ghosn, Christine Durier, Carla Tachot, Eric Tartour, Amel Touati, Tabassome Simon, Brigitte Autran, Inmaculata Ortega Perez, Erica Telford, Jeremy K Ward, David Michels, Laurence Meyer, Alexandra Rousseau, Laurence Berard, Xavier de Lamballerie & Odile Launay





# Outline



What we knew

What happened

What we learned

What we still do not know

# Clinical presentation



- Different clinical presentation
  - Localized
  - Lesions located around genitals + throat
- Mortality less severe < 1%</li>





Mailhe, CMI, 2022

# Clinical presentation



- Different clinical presentation
  - Localized
  - Lesions located around genitals + throat
- Mortality less severe < 1%</li>
- Except





Mailhe, CMI, 2022

# Clinical presentation



# Mpox in people with advanced HIV infection: a global case series

Oriol Mitjà\*, Andrea Alemany\*, Michael Marks\*, Jezer I Lezama Mora, Juan Carlos Rodríguez-Aldama, Mayara Secco Torres Silva, Ever Arturo Corral Herrera, Brenda Crabtree-Ramirez, José Luis Blanco, Nicolo Girometti, Valentina Mazzotta, Aniruddha Hazra, Macarena Silva, Juan José Montenegro-Idrogo, Kelly Gebo, Jade Ghosn, María Fernanda Peña Vázquez, Eduardo Matos Prado, Uche Unigwe, Judit Villar-García, Noah Wald-Dickler, Jason Zucker, Roger Paredes, Alexandra Calmy, Laura Waters, Cristina Galvan-Casas, Sharon Walmsley, Chloe M Orkin, on behalf of SHARE-NET writing group

Lancet, 2023

- Severe lesions if CD4 <200 /mm<sup>3</sup>
- Necrotizing if CD4 <100 /mm<sup>3</sup>
- 25% death











ANRS 174 Doxyvac trial: High risk HSH cohort study




IRR: 64%



### **Immunogenicity**





Luong Nguyen, ECCMID, 2023

Zaeck, Nature Med, 2022


→ But only humoral!


10,240



### **Immunogenicity**







Luong Nguyen, ECCMID, 2023

Zaeck, Nature Med, 2022


→ But only humoral!




Michala P. Dapary, Ph.D., Jasagh Darbert, Ph.D., Avva N. Chard, Ph.D., rood handlery, M.E., Caraster, Maulia, M.Fot, Sin Barbey, B.D., Abramira F. Daber, Ph.D., Cary Sures, M.S., America C. Carry, M.D.,

Deptd R. Littin, W.D., Astern L. Cohen, M.D., Demona Randmann, M.P.H., Daniel C. Papta, Ph.D., Jacquellov L. Gerbayt, M.D., and Leona R. Feldonov, W.D.

### **Immunogenicity**



Luong Nguyen, ECCMID, 2023



Zaeck, Nature Med, 2022

**→** But only humoral!

### **Epidemiology**

Real-world effectiveness of a single dose of

mpox vaccine in males


Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously
Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons —
29 U.S. Jurisdictions, May 22–September 3, 2022

Jenzilic I. Ferrat, MPH<sup>1</sup>; Northand M. Lovie, Pol<sup>2</sup>; Kenzely Houde, MPH<sup>1</sup>; Michalle Canzing, MPH<sup>1</sup>; Any Forbegill, PhD<sup>1</sup>-7, Annaoda B. Byne, PhD<sup>1</sup>-7, Anna M. Sadahan, PhD<sup>1</sup>


→ Only observational, case/control



### **Immunogenicity**



Luong Nguyen, ECCMID, 2023



Zaeck, Nature Med, 2022

### S Epidemiology

Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons — 29 U.S. Jurisdictions, May 22–September 3, 2022

Morbidity and Mortality Weekly Report

Jennite L. Farm, MPH; Anthraid M. Lovic, Pal.)\*; Karandy Houdy House, MPH; Michalle Caraing, MPH; Anty Frahagill, PhDP\*; Annanda B. Byan, PhDP; Malay L. Cohen, MDP; Johna Varson, MPH, McD\*; Bendyn Bendd, MPHP; Enricy Chren, MS\*\* Anthrain Facility, Nikki Dagdorous, MPH\*; Sandrain Facility, Nikki Dagdorous, MPH\*; Sandrain Facility, MPH\*; Bendyn Brandon Benns, MPH\*; Brandon Benns, MPH\*; Enricy Hundernan, MPH\*; Bardy Banagin, MPH\*; Bendyn Brandon Benns, MPH\*; Brandon

Real-world effectiveness of a single dose of mpox vaccine in males

The state of th

against Mpox Disease in the United States status P. Dayan, N.D. Joseph Coulon, N.D. Avon S. Court, N.D. Ned Sanding, M.E. Ouelder, March, 1975. Lis Sallon, N.D. Alteretty P. Daber, N.D. Care State St. Avende G. Care, M.D. David S. Link, W.D. Aden L. Care, M.D. Davenda G. Care, M.D. Avende G. Care, M.D. H. Davenda G. Care, M.D. Davenda G.

Vaccine Effectiveness of JYNNEOS

Spot S. Life, W.D., Adres L. Colen, W.D., Darross Bardrane, W.P.H., Dased C. Papel, Ps.D., Jacquelles L. Gerbyt, et C., and Laura E. Feldosen, Ph.D.



### **Vaccination likely to be effective**

- Less effective than for small pox (60-80%) for infection
- Probably with milder forms
- More effective with previous small pox immunization

# Outline



What we knew


What happened

What we learned

What we still do not know

# In the end...





# **Unanswered questions**



### What really reduced cases?

- Vaccination
- Behavioral change
- Sexual network saturation

### What is the effectiveness of the vaccine

- On immunocompromised (HIV?)
- Route of administration
- Need for booster dose?
- Articulation with antiviral (teicovirimat)

# Cảm ơn



- ANRS | MIE
- VAAC
- HPMU

- Monkey Vax study team
  - Funders: ANRS | MIE and MOH
  - Co-investigator: Pr. O. Launay, Pr. J. Ghosn
  - Sponsor : AP-HP
  - Analysis : CESP/SC-10
  - Virology : AMU
  - Immunology : Inserm

Questions? liem.luong@aphp.fr